Result Page 30 for Pfizer news & latest pictures from ibtimes.com

Lilly forecasts sidestep 2011-2014 patent cliff

Eli Lilly and Co forecast 2010 earnings in line with Wall Street expectations but gave no hint of how profit might pan out after its biggest drugs lose patent protection between 2011 and 2014.

Pfizer told to pay $28 mln damages in Prempro case

A Philadelphia jury on Monday ordered Pfizer Inc (PFE.N) to pay $28 million in punitive damages to a breast cancer survivor who had used the company's hormone replacement drugs for 11 years.

U.S. Democrats demand analysis of drug price rises

Democrats in the U.S. Congress are seeking government investigations into recent price increases of brand-name prescription drugs, as lawmakers finalize an overhaul of the healthcare system.

Roche announces late-stage trial for heart drug

Swiss drugmaker Roche Holding AG said on Wednesday it would conduct a new late-stage trial to evaluate the effect of one of its drug candidates in combating a thickening of the arteries in patients.

More news

Lilly profit tops Street view, but shares fall

Eli Lilly and Co posted third-quarter profit well above Wall Street expectations on Wednesday on strong performance of its major prescription drugs and lower taxes, but it said an inventory benefit that helped results might reverse in the fourth quarter.

Pfizer third-quarter profit rises

Pfizer Inc reported higher third-quarter profit as aggressive cost-cutting offset a negative foreign exchange impact and declining sales of drugs, including those facing competition from cheaper generics.

Wall St dips as housing, PPI data offsets earnings

U.S. stocks fell on Tuesday as strong quarterly results from bellwethers such as Apple and Caterpillar were offset by disappointing data on housing starts and inflation.

Caterpillar, Apple profits push futures higher

U.S. stock index futures rose on Tuesday after strong quarterly results from bellwethers Apple and Caterpillar pointed to a solid earnings season.

Solid earnings boost futures

U.S. stock index futures rose on Tuesday after strong quarterly results from bellwethers Apple and Caterpillar pointed to a strong earnings season.

U.S. stock futures signal gains as Apple, TI please

* U.S. stock index futures pointed to a higher open on Wall Street on Tuesday, after strong quarterly results from bellwethers Apple (AAPL.O) and Texas Instruments (TXN.N) pleased investors.

Stock futures signal gains as Apple, TI please

U.S. stock index futures pointed to a higher open on Wall Street on Tuesday, after strong quarterly results from bellwethers Apple and Texas Instruments pleased investors.

U.S. seeks more information on Novartis lung drug

U.S. regulators have asked for more information on dosing proposed for a drug from Novartis AG for smoker's lung, or chronic obstructive pulmonary disease, the Swiss group said on Monday.

Pfizer wins U.S. antitrust approval to buy Wyeth

Pfizer Inc won U.S. and Canadian antitrust approval to buy smaller rival Wyeth on Wednesday, and will close the $66 billion deal this week, the world's largest drugmaker said.

Foreign takeovers of drugmakers worry Brazil-report

Brazil's government will use regulation and its financial muscle to trump a wave of foreign takeovers in the nation's pharmaceutical industry, the daily newspaper Valor Economico said on Wednesday, citing a top official.

Cancer, bowel drugs on FDA safety scrutiny list

More than a dozen drugs including a cancer therapy and a bowel medicine are under early scrutiny for potential side effects, U.S. regulators said in a quarterly list released on Thursday.

Glaxo eyes Dr Reddy's as Big Pharma hunts in India

Western drugmakers are stepping up the hunt for emerging market tigers in India.

Scientists develop antidote for new class of drugs

A new compound can quickly counteract the action of an emerging class of drugs, offering a way to reverse the drugs' actions if a patient develops serious side effects, U.S. researchers said on Sunday.

Abbott, J&J to bulk up in Europe, vaccines

U.S. healthcare companies Abbott Laboratories and Johnson & Johnson announced deals worth almost 5 billion euros ($7.3 billion) with European rivals on Monday, aimed at securing vaccines and other products key to future growth.

Johnson & Johnson buys 18 pct stake in Crucell

U.S. diversified health care company Johnson & Johnson has bought an 18 percent stake in biotech firm Crucell for 302 million euros ($444 million) as part of a flu vaccine development deal, the Dutch company said on Monday.

Abbott, Johnson & Johnson bulk up in Europe

U.S. healthcare companies Abbott Laboratories and Johnson & Johnson announced deals worth almost 5 billion euros ($7.3 billion) with European rivals on Monday aimed at securing vaccines and other products key to future growth.

RPT-Merck, Wyeth execs see Big Pharma survival edge

Large drug companies have inherent advantages -- including cash to conduct expensive drug studies and to assure survival when trials fail -- that will be increasingly important in coming years, senior executives of Wyeth and Merck and Co said on Tuesday.

PFIZER

Pages